Palvella Therapeutics (NASDAQ:PVLA) reported transformative full-year 2025 financial results and a significant corporate update on March 31, 2026, headlined by the successful clinical validation of its lead rare disease program.
The company announced positive topline results from its Phase 3 SELVA clinical trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel for the treatment of microcystic lymphatic malformations (LMs).
The positive Phase 3 data serves as the foundation for Palvella’s regulatory strategy, with the company now actively planning for a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) in the second half of 2026.
If approved, QTORIN™ rapamycin would become the first FDA-approved therapy specifically indicated for this chronically debilitating genetic skin disease.
To support the transition toward a commercial-stage entity, Palvella successfully completed an upsized equity financing post-year-end.
This capital raise resulted in a pro forma cash position of approximately $274 million, significantly strengthening the balance sheet compared to the $58 million in cash and cash equivalents reported as of December 31, 2025.
Financially, Palvella reported a net loss of $41.7 million for the full year 2025.
Research and development (R&D) expenses totaled $22.8 million, reflecting the intensive clinical activity surrounding the SELVA trial and the expansion of the QTORIN™ pipeline.
General and administrative (G&A) expenses were $15.8 million for the year.
The company’s 2026 roadmap includes several high-impact catalysts.
Palvella plans to initiate a Phase 3 trial for QTORIN™ rapamycin in cutaneous venous malformations (VMs) in the second half of the year.
Additionally, the company introduced a new development program, QTORIN™ pitavastatin, for the treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), further diversifying its rare dermatology portfolio.